comparemela.com

Latest Breaking News On - Early stage nsclc - Page 1 : comparemela.com

Metastatic NSCLC (mNSCLC) Biomarkers and Prognostic Factors Compared to Early-Stage NSCLC

Specialists review specific prognostic factors and biomarkers that help guide treatment selection for patients with metastatic NSCLC (mNSCLC) and discuss if these biomarkers differ from those observed in early-stage NSCLC.

David carboneMartin dietrichNon small cell lung cancerPrognostic factorsTreatment selectionEarly stage nsclcPd l1 gt 50Pd l1 lt 49Pl l1 lt 1

Neoadjuvant Therapy in Early NSCLC Treatment

A panel discusses the role of neoadjuvant therapy in the current treatment approach for early stages of NSCLC.

Erina gillaspiePatrick fordeDavid carboneNon small cell lung cancerTage three diseaseNeoadjuvant therapyCurrent treatment approachEarly stage nsclc

Early-Stage NSCLC Standard Treatments

Experts discuss the current standard treatment options for patients diagnosed with early-stage NSCLC [non-small cell lung cancer].

Tommy damicoSalma jabbourDavid carboneErina gillaspieLung cancer study groupDrs gillaspieTommyd amicoNon small cell lung cancerCurrent treatment optionsEarly stage nsclcOncologic outcomesSurgical outcomesIncreased morbidityRecurrence rate

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Neoadjuvant durvalumabJohn heymachAdjuvant durvalumabPartnership withNon small cell lung cancerEarly stage lung cancerEarly stage nsclcDurvalumab therapyOverall survivalProgression free survivalEvent free survivalPathologic complete responsePd l1 expressionPd l1 levelAdverse eventsDrug adverse event

Neoadjuvant Atezolizumab Followed by Adjuvant Atezolizumab May Benefit Select Patients With Early-stage NSCLC

Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.

United statesDaiichi sankyoLos angelesKarenl reckampLung institute at cedarsSinai medical centerDivision of medical oncologyClinical researchSinai samuel oschin comprehensive cancer instituteMedical oncologyLung instituteCedars sinai medical centerElevation oncologySeattle geneticsEarly stage nsclcAdjuvant atezolizumab

vimarsana © 2020. All Rights Reserved.